Publicaciones en colaboración con investigadores/as de Centre Léon Bérard (8)

2024

  1. Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study

    Gynecologic Oncology, Vol. 186, pp. 182-190

  2. Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer

    Bulletin du Cancer, Vol. 111, Núm. 3, pp. 277-284

2022

  1. Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial

    Gynecologic Oncology, Vol. 164, Núm. 2, pp. 254-264

  2. Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial

    European Journal of Cancer, Vol. 174, pp. 221-231

2020

  1. PARP inhibitors in ovarian cancer

    New England Journal of Medicine

2019

  1. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer

    New England Journal of Medicine, Vol. 381, Núm. 25, pp. 2416-2428

2017

  1. European society of Gynaecological Oncology (ESGO) guidelines for ovarian cancer surgery

    International Journal of Gynecological Cancer, Vol. 27, Núm. 7, pp. 1534-1542

2016

  1. European society of gynaecologic oncology quality indicators for advanced ovarian cancer surgery

    International Journal of Gynecological Cancer, Vol. 26, Núm. 7, pp. 1354-1363